Evidence map›Paper›PMID 31118681›Full record

ArticleOncoTargets and therapy2019

High feasibility of cytological specimens for detection of

Limin Zhang, Yan Wang, Chao Zhao, Jinpeng Shi, Sha Zhao, Xiaozhen Liu, Yijun Jia, Tao Zhu, Tao Jiang, Xuefei Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Advanced lung adenocarcinoma patient withAnnals of translational medicine · 2022
    Article
  3. Detection ofFrontiers in cell and developmental biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Limin ZhangDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.
Yan WangDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.
Chao ZhaoDepartment of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, bug_lily2003@163.com.
Jinpeng ShiDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.
Sha ZhaoDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.
Xiaozhen LiuDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.
Yijun JiaDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.
Tao ZhuDepartment of Laboratory Medicine, Zhecheng People's Hospital, Shangqiu, Henan 476200, People's Republic of China.
Tao JiangDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.
Xuefei LiDepartment of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, bug_lily2003@163.com.
Caicun ZhouDepartment of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China, caicunzhoudr@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur previous study demonstrated that cytological specimens can be used as alternative samples for detecting anaplastic lymphoma kinase ( PATIENTS AND

methodsA total of 2,538 patients with advanced NSCLC, including 2,101 patients with cytological specimens and 437 patients with tumor tissues, were included in this study. All patients were screened for

resultsAmong 2,101 patients with cytological specimens, the average concentration of RNA acquired from cytological specimens was 47.68 ng/μL (95% CI, 43.24-52.62), which was lower than the average of 66.54 ng/μL (95% CI, 57.18-76.60,

conclusionThis study shows that cytological specimens can be utilized as alternative samples for

Indexed as

crizotinibcytological specimensnon-small-cell lung cancerreverse transcriptase polymerase chain reactionROS1ROS proto-oncogene 1 receptor tyrosine kinaseRT-PCR

Identifiers

PMID31118681
PMCPMC6501702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.